Fulgent Genetics operates a clinical laboratory business focused on genetic and genomic testing using next-generation sequencing and related methods. Its menu spans hereditary disease panels, oncology-related testing, and other molecular diagnostics ordered by clinicians and health systems. The company built scale during the pandemic testing period and continues to emphasize broad, high-throughput genetic test offerings.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 73.5 | — | -11.5 | — |
| Q2 2025 | 81.8 | — | -19 | — |
| Q3 2025 | 84.1 | — | -6.6 | — |
| Q4 2025 | 83.3 | — | -23.4 | — |
| Q1 2026 | 71.1 | -3.2% | -24.8 | — |
| Q2 2026 | 85.4 | 4.4% | -29.5 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Katapult Holdings, Inc. (KPLT), Shattuck Labs, Inc. (STTK), Silence Therapeutics plc (SLN), Pacific Biosciences of California, Inc. (PACB), LightPath Technologies, Inc. (LPTH), The Honest Company, Inc. (HNST)